Physician profile
Mark D Holm
NPI 1831189240
$317,710.55
in general payments reported to CMS, 2019-2025
9 companies · $46K in 2025
The $46K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $32K · 2021: $36K · 2022: $54K · 2023: $8,994 · 2024: $21K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Travel and Lodging: $11K · Food and Beverage: $1,753 · Education: $91.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,610.19 |
| Travel and Lodging | $10,878.66 |
| Food and Beverage | $1,753.46 |
| Education | $91.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $159,332.53 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $55,469.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $34,690.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $27,767.48 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20,210.79 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $19,890.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.83 | 2019 | |
| Glaxosmithkline, LLC. | $83.38 | 2022 | |
| Amarin Pharma, INC. | $74.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Holm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.